The key patient characteristics, demographics, and results of CVD-REAL 2 (Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors), EMPA-REG (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose), DECLARE-TIMI (Dapagliflozin Effect on Cardiovascular Events-Thrombolysis in Myocardial Infarction), and CANVAS (Canagliflozin Cardiovascular Assessment Study) are compared in Table 4. This evidence concerns the gene SLC5A2 and diabetes mellitus.